{
    "clinical_study": {
        "@rank": "26755", 
        "arm_group": [
            {
                "arm_group_label": "Concomitant V260 and DTP-IPV", 
                "arm_group_type": "Experimental", 
                "description": "V260 (2 mL oral dose) and DTP-IPV (0.5 mL subcutaneous injection) administered concomitantly at Visit 2, Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4)."
            }, 
            {
                "arm_group_label": "Staggered V260 and DTP-IPV", 
                "arm_group_type": "Experimental", 
                "description": "V260 (2 mL oral dose) administered at Visit 1, Visit 3 (6 weeks after Visit 1), and Visit 5 (6-8 weeks after Visit 3) and DTP-IPV (0.5 mL subcutaneous injection) administered at Visit 2, Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4)."
            }
        ], 
        "brief_summary": {
            "textblock": "The study will evaluate the immunogenicity of the Diphtheria, Tetanus, Pertussis and\n      Inactivated Poliovirus Vaccine (DTP-IPV) with concomitant administration of V260 (RotaTeq\u2122)\n      in healthy Japanese infants. The hypothesis to be tested is that the antibody response rates\n      to DTP-IPV with concomitant administration of V260 are non-inferior to those with staggered\n      administration of V260."
        }, 
        "brief_title": "Immunogenicity and Safety of Concomitant Administration of V260 (RotaTeq\u2122) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rotavirus Disease", 
        "condition_browse": {
            "mesh_term": [
                "Diphtheria", 
                "Whooping Cough", 
                "Rotavirus Infections"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Japanese participant\n\n          -  Age 6 weeks through <11 weeks (42 to 76 days from date of birth) at Visit 1\n\n        Exclusion Criteria:\n\n          -  History of hypersensitivity and/or anaphylaxis to any of the product ingredients in\n             V260 or DTP-IPV\n\n          -  Gastrointestinal disorder, growth retardation, or failure to thrive\n\n          -  History of intussusception\n\n          -  Untreated congenital gastrointestinal disorder (such as Meckel diverticulum)\n\n          -  Known or suspected impairment of immunological function, including severe\n             immunodeficiency (SCID)\n\n          -  Cardiovascular, renal, liver, or blood disease\n\n          -  History of convulsion\n\n          -  Undergoing immunosuppressive therapy or living with a close relative with congenital\n             immune deficiency\n\n          -  Prior vaccination of rotavirus vaccine and/or DTP-IPV vaccine\n\n          -  Live vaccine received within 28 days or inactivated vaccine received within 7 days\n\n          -  At high risk for tuberculosis exposure"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "76 Days", 
            "minimum_age": "42 Days"
        }, 
        "enrollment": {
            "#text": "190", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01926015", 
            "org_study_id": "V260-060", 
            "secondary_id": "132252"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Concomitant V260 and DTP-IPV", 
                    "Staggered V260 and DTP-IPV"
                ], 
                "description": "Live, oral, pentavalent vaccine containing 5 human-bovine reassortant rotavirus strains", 
                "intervention_name": "V260", 
                "intervention_type": "Biological", 
                "other_name": "RotaTeq\u2122"
            }, 
            {
                "arm_group_label": [
                    "Concomitant V260 and DTP-IPV", 
                    "Staggered V260 and DTP-IPV"
                ], 
                "description": "Diphtheria, tetanus, pertussis, inactivated polio vaccine used as part of the Japanese vaccination schedule", 
                "intervention_name": "DTP-IPV", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Tetrabik\u2122", 
                    "BIKEN"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 29, 2014", 
        "number_of_arms": "2", 
        "official_title": "Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Antibody Response Rates to Diphtheria Toxin, Tetanus Toxin, Pertussis Toxin, Pertussis Filamentous Hemagglutinin (FHA), and Polio Virus Type 1/2/3", 
            "safety_issue": "No", 
            "time_frame": "From 4 to 6 weeks after the third DTP-IPV vaccination"
        }, 
        "removed_countries": {
            "country": "Japan"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01926015"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of Participants Reporting Adverse Events with an Incidence \u22651%", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 14 days after each visit (Visits 1-6)"
            }, 
            {
                "measure": "Percentage of Participants Reporting Adverse Events of Special Interest", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 14 days after each visit (Visits 1-6)"
            }, 
            {
                "measure": "Percentage of Participants Reporting Adverse Events of Special Interest", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 14 days after the last visit (Visit 6)"
            }, 
            {
                "measure": "Geometric Mean Titer (GMT) of Diphtheria Toxin, Tetanus Toxin, Pertussis Toxin, Pertussis FHA, and Polio Virus Type 1/2/3", 
                "safety_issue": "No", 
                "time_frame": "From 4 to 6 weeks after the third DTP-IPV vaccination"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}